First Berlin cuts Rakovina Therapeutics price target to CAD 0.25, downgrades to Add

Reuters2026/09/02 16:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

First Berlin cut its rating on Rakovina Therapeutics to Add from Buy, citing mixed progress across its AI-driven preclinical pipeline.
Price target slashed to CAD 0.25 from CAD 4, reflecting higher dilution assumptions and a much lower share price since coverage began.
Research highlighted kt-5000 as the main value driver, pointing to CNS penetration and early in-vivo efficacy versus AstraZeneca’s ceralasertib.
kt-2000 PARP1 work lagged expectations on pharmacokinetics versus AstraZeneca’s AZD9574, prompting a shift in licensing focus toward kt-5000.
Model assumes a 2028 licensing deal for kt-5000 with a CAD 30 million upfront, capital raises in 2026-2027, 168 million fully diluted shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26726) on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

First Berlin cuts Rakovina Therapeutics price target to CAD 0.25, downgrades to Add

You may also like

Crypto prices